The effects of PPAR-gamma ligand pioglitazone on platelet aggregation and arterial thrombus formation

Cardiovasc Res. 2005 Mar 1;65(4):907-12. doi: 10.1016/j.cardiores.2004.11.027.

Abstract

Background: It has been suggested that peroxisome proliferator-activated receptor (PPAR)-gamma ligands reduce the development of atherosclerosis and myocardial ischemia-reperfusion injury; both of these phenomena are associated with platelet activation. We postulated that PPAR-gamma activation would inhibit platelet activation and intra-arterial thrombus formation.

Methods and results: Sprague-Dawley rats were fed chow mixed with pioglitazone (1 or 10 mg/kg/day) for 7 to 10 days. A filter soaked in 30% FeCl(3) was applied around the abdominal aorta to study the patterns of arterial thrombogenesis. The aortic blood flow was continuously monitored using an ultrasonic Doppler flow probe. ADP and arachidonic acid-induced platelet aggregation and the expression of constitutive nitric oxide synthase (cNOS) and thrombomodulin in aorta were measured. Pioglitazone feeding delayed the time to occlusive thrombus formation by 40% (P<0.01 vs. control, n=9) without affecting the weight of the thrombus. ADP- as well as arachidonic acid-induced platelet aggregation was also inhibited by pioglitazone feeding (P<0.01 vs. control, n=9). Pioglitazone feeding also upregulated the aortic expression of cNOS and thrombomodulin; both are considered important factors in platelet aggregation and thrombus formation in vivo. The effect of a high dose (10 mg/kg/day) of pioglitazone was not more potent than that of a low dose (1 mg/kg/day).

Conclusion: These results indicate that pioglitazone administration decreases platelet aggregation and delays intra-arterial thrombus formation in rats, at least partially, by an increase in the expression of cNOS and thrombomodulin.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Aorta / metabolism
  • Endothelium, Vascular / metabolism
  • Gene Expression Regulation / drug effects
  • Hypoglycemic Agents / therapeutic use*
  • Ligands
  • Male
  • Nitric Oxide Synthase / genetics
  • Nitric Oxide Synthase / metabolism
  • PPAR gamma / agonists
  • PPAR gamma / metabolism*
  • Pioglitazone
  • Platelet Aggregation / drug effects*
  • RNA, Messenger / genetics
  • Rats
  • Rats, Sprague-Dawley
  • Thiazolidinediones / therapeutic use*
  • Thrombomodulin / genetics
  • Thrombomodulin / metabolism
  • Thrombosis / blood
  • Thrombosis / pathology
  • Thrombosis / prevention & control*

Substances

  • Hypoglycemic Agents
  • Ligands
  • PPAR gamma
  • RNA, Messenger
  • Thiazolidinediones
  • Thrombomodulin
  • Nitric Oxide Synthase
  • Pioglitazone